Sight Diagnostics specializes in utilizing advanced computer vision and machine learning technology in the realm of blood diagnostics.
Sight’s initial product, the Parasight platform, is the world’s first automated microscopy device for Malaria diagnosis. Malaria is still one of the world’s deadliest diseases, largely due to ineffective and costly diagnosis. This revolutionary platform provides better accuracy and ease of use. This product completed development and commercialization and is being sold and used in medical centers in India, Africa and Europe, becoming the first new commercial diagnostic in the malaria field since the inception of PCR.
The company is now applying its technology to the $20 billion complete blood count (CBC) market, developing a point-of-care CBC platform which will provide a 5 point differential blood count and will be available for use in doctors’ offices and emergency medical centers around the world.
Beyond malaria and CBC, Sight’s novel computer vision technology has the potential to unlock advanced diagnostic approaches to numerous additional diseases and provide more accurate and cheaper testing for the patient.
The company was founded in 2011, and is based in central Tel Aviv and in Jerusalem.